Tuesday, 13 January 2026
  
Login

Australia's most trusted
source of pharma news

Tuesday, 13 January 2026
News

Drug supply squeeze until mid-year

Posted 13 January 2025 PM 

Supply constraints of Viatris’ PBS listed pancreatic enzyme supplement Creon are expected to continue through the first half of 2026.

The US headquartered pharmaceutical company created from the merger of Mylan and Upjohn in 2020, first notified the TGA that it anticipated supply constraints related to Creon 25,000 unit and Creon 35,000 unit capsules in August 2025 to last for the remainder of the year, due to “an unexpected global increase in demand”.

To see the whole article, please login

Popular

New Year, new pharma on the PBS
Job moves mark start of 2026
TGA kicks off with first-in-class nod
Where are they going? Leaders exit
Latest Jobs
MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.


Subscribe
 
© 2003 - 2026 Lush Media | Privacy Statement | Subscribe to Pharma in Focus
home